SUBSCRIBE
SUBSCRIBE
News   Deals

Pediatric Asthma Programs With CyDex, Inc. Captisol Technology Acquired by AstraZeneca PLC

October 3, 2007 | 
1 min read
LENEXA, Kan.--(BUSINESS WIRE)--CyDex, Inc. today announced that rights to pediatric asthma development programs that include CyDex’s Captisol-Enabled® technology have been acquired from Verus Pharmaceuticals, Inc. by AstraZeneca.
Mergers & acquisitions
AstraZeneca
MORE ON THIS TOPIC
Podcast
Sentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water
July 1, 2026
 · 
2 min read
 · 
Jef Akst
Upward arrow on the background of the flag of China. Paper plane. Economic recovery. Copy space. Business. Background.
China
Deerfield bets up to $1.6B to snag autoimmune asset in China for Boulevard
June 30, 2026
 · 
1 min read
 · 
Annalee Armstrong
Solution Concept with Handshake on Chalkboard Background
Mergers & acquisitions
Zymeworks adds lung disease drug, royalty deals in nearly $1B pick up of Theravance
June 29, 2026
 · 
2 min read
 · 
Annalee Armstrong
Business handshake trendy halftone art collage banner template. Partnership concept, successful agreement, closing a deal, securing a contract. Modern retro cut out vector illustration
Mergers & acquisitions
Ipsen makes up to $1.75B blood cancer bet with Kartos buyout
June 29, 2026
 · 
2 min read
 · 
Tristan Manalac